Cargando…

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

BACKGROUND: A pre-specified meta-analysis of cardiovascular (CV) events from 21 phase 2b/3 dapagliflozin clinical trials was undertaken to characterise the CV profile of dapagliflozin. This showed no increase in CV risk with dapagliflozin compared with control (placebo or comparator treatment) with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sonesson, Christian, Johansson, Peter A., Johnsson, Eva, Gause-Nilsson, Ingrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761166/ https://www.ncbi.nlm.nih.gov/pubmed/26895767 http://dx.doi.org/10.1186/s12933-016-0356-y

Ejemplares similares

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
por: Cefalu, William T., et al.
Publicado: (2015)

Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
por: Ptaszynska, Agata, et al.
Publicado: (2015)

The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial
por: McEwan, Phil, et al.
Publicado: (2021)

Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
por: Shao, Shih-Chieh, et al.
Publicado: (2019)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos, Ioannis, et al.
Publicado: (2019)

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Yavin, Yshai, et al.
Publicado: (2016)

Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
por: Johansson, Lars, et al.
Publicado: (2020)

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
por: Fioretto, Paola, et al.
Publicado: (2016)

Dapagliflozin Improves Cardiac Autonomic Function Measures in Type 2 Diabetic Patients with Cardiac Autonomic Neuropathy
por: Balcıoğlu, Akif Serhat, et al.
Publicado: (2022)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)
por: Kinguchi, Sho, et al.
Publicado: (2019)

Dissimilar impact of type 2 diabetes on cardiovascular outcomes according to age categories: a nationwide population study from Hungary
por: Kiss, Zoltán, et al.
Publicado: (2018)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
por: Soga, Fumitaka, et al.
Publicado: (2018)

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
por: Fuchigami, Ayako, et al.
Publicado: (2020)

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
por: Waijer, Simke W., et al.
Publicado: (2022)

Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure
por: Tanaka, Hidekazu, et al.
Publicado: (2020)

Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis
por: Memon, Rahat A, et al.
Publicado: (2022)

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
por: Lee, Dustin M., et al.
Publicado: (2018)

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
por: Shigiyama, Fumika, et al.
Publicado: (2017)

Sex-specific associations between adolescent categories of BMI with cardiovascular and non-cardiovascular mortality in midlife
por: Furer, Ariel, et al.
Publicado: (2018)

Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
por: Fioretto, Paola, et al.
Publicado: (2016)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors
por: Cea Soriano, Lucia, et al.
Publicado: (2015)

Triple therapy with low‐dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2019)

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
por: Mosenzon, Ofri, et al.
Publicado: (2022)

The effect of dapagliflozin treatment on epicardial adipose tissue volume
por: Sato, Takao, et al.
Publicado: (2018)

Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity
por: Ulusan, Sebahat, et al.
Publicado: (2023)

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
por: Solini, Anna, et al.
Publicado: (2017)

Cardiovascular risk factors in Assyrians/Syrians and native Swedes with type 2 diabetes: a population-based epidemiological study
por: Taloyan, Marina, et al.
Publicado: (2009)

Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
por: Sposito, Andrei C., et al.
Publicado: (2021)

Bone markers and cardiovascular risk in type 2 diabetes patients
por: Zwakenberg, Sabine R., et al.
Publicado: (2018)

Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus
por: Kohlmorgen, Christina, et al.
Publicado: (2021)

Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study
por: Seong, Jong-Mi, et al.
Publicado: (2020)

Cardiovascular organ damage in type 2 diabetes mellitus: the role of lipids and inflammation
por: Kozakova, Michaela, et al.
Publicado: (2019)

Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aallfep0n7kpf6ap58e7hlj2mt